Meta Analysis: Donepezil in the Treatment of Cognitive Impairment and Dementia in Patients with Parkinson’s Disease

Ela A. Barcelon, Leah L. Shiong Shu and Paul Matthew D. Pasco

Department of Neurosciences, College of Medicine and
Philippine General Hospital, University of the Philippines Manila

Objective. Evaluate the efficacy and safety of Donepezil in improving cognitive function of patients with Parkinson's disease diagnosed to have cognited impairment or dementia.

Methods. Meta-analysis of randomized controlled trials comparing Donepezil versus placebo in the management of Parkinson's disease patients with cognitive impairment or dementia. Mean differences were computed using RevMan Version 5.1.

Results. Fifty-five studies were screened for inclusion in this meta-analysis. Only four studies met the inclusion and exclusion criteria. Administration of Donepezil 10 mg/tab for at least 4 weeks showed statistically significant improvement in the cognitive function or Parkinson's disease patients with dementia or cognitive impairment in terms of MMSE. There were no significant differences in the other scales measured. Incidence of adverse events was found to be higher in the Donepezil group, but this was not statistically significant.

Conclusion. This study successfully demonstrated the efficacy of Donepezil in cognitively impaired Parkinson's disease patient in the improvement of MMSE without significant impact on motor symptoms.

Key Words: Donepezil, Parkinson's Dementia, dementia, Parkinson's Disease, cognitive impairment